Mimedx (MDXG) Common Equity (2010 - 2026)

Mimedx has disclosed Common Equity across 17 years of filings, most recently posting $242.9 million for Q1 2026.

• Common Equity for Q1 2026 came in at $242.9 million, up 19.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $242.9 million (up 19.81% YoY), and the FY2025 annual result was $256.5 million, up 32.85% from the prior year.
• Common Equity came in at $242.9 million for Q1 2026 at Mimedx, down from $256.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $256.5 million in Q4 2025 to a low of -$19.5 million in Q3 2022.
• The 5-year median for Common Equity is $155.7 million (2024), against an average of $112.4 million.
• Across the five-year window, Common Equity slumped 22036.59% in 2022 and surged 13509.62% in 2024, its largest moves.
• Mimedx's Common Equity stood at -$18.0 million in 2022, then soared by 893.4% to $142.7 million in 2023, then surged by 35.31% to $193.1 million in 2024, then soared by 32.85% to $256.5 million in 2025, then retreated by 5.31% to $242.9 million in 2026.
• The last three Common Equity figures came in at $242.9 million (Q1 2026), $256.5 million (Q4 2025), and $238.9 million (Q3 2025), per Business Quant data.